UK Markets close in 3 hrs 10 mins

1 Reason to Sell Novavax Stock, and 1 Reason to Buy

·3-min read

This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.